Literature DB >> 16635618

Intra-aortic balloon counterpulsation.

Jeffrey C Trost1, L David Hillis.   

Abstract

Intra-aortic balloon counterpulsation (IABP) is sometimes used in critically ill patients with cardiac disease. By increasing diastolic arterial pressure and decreasing systolic pressure, it reduces left ventricular afterload. IABP may be beneficial in subjects with cardiogenic shock, mechanical complications of myocardial infarction, intractable ventricular arrhythmias, or advanced heart failure or those who undergo "high-risk" surgical or percutaneous revascularization, but the evidence to support its use in these patient groups is largely observational. Contraindications to IABP include severe peripheral vascular disease as well as aortic regurgitation, dissection, or aneurysm. The potential benefits of IABP must be weighed against its possible complications (bleeding, systemic thromboembolism, limb ischemia, and, rarely, death).

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16635618     DOI: 10.1016/j.amjcard.2005.11.070

Source DB:  PubMed          Journal:  Am J Cardiol        ISSN: 0002-9149            Impact factor:   2.778


  21 in total

1.  Intra-aortic balloon pumping reduces the increased arterial load caused by acute cardiac depression, modifying central and peripheral load determinants in a time- and flow-related way.

Authors:  Daniel Bia; Edmundo I Cabrera-Fischer; Yanina Zócalo; Ricardo L Armentano
Journal:  Heart Vessels       Date:  2011-11-09       Impact factor: 2.037

Review 2.  The use of computational fluid dynamics in the development of ventricular assist devices.

Authors:  Katharine H Fraser; M Ertan Taskin; Bartley P Griffith; Zhongjun J Wu
Journal:  Med Eng Phys       Date:  2010-11-13       Impact factor: 2.242

3.  The future of adult cardiac assist devices: novel systems and mechanical circulatory support strategies.

Authors:  Carlo R Bartoli; Robert D Dowling
Journal:  Cardiol Clin       Date:  2011-11       Impact factor: 2.213

4.  Design of a pulsatile flow facility to evaluate thrombogenic potential of implantable cardiac devices.

Authors:  Sivakkumar Arjunon; Pablo Hidalgo Ardana; Neelakantan Saikrishnan; Shalv Madhani; Brent Foster; Ari Glezer; Ajit P Yoganathan
Journal:  J Biomech Eng       Date:  2015-02-11       Impact factor: 2.097

5.  IABP plus ECMO-Is one and one more than two?

Authors:  Sebastian Nuding; Karl Werdan
Journal:  J Thorac Dis       Date:  2017-04       Impact factor: 2.895

6.  [Influence of ECMO and IABP on coronary blood flow. Valuable combination or waste of resources?].

Authors:  T Schroeter; M Vollroth; M Höbartner; M Sauer; M Mende; F W Mohr; M Misfeld
Journal:  Med Klin Intensivmed Notfmed       Date:  2014-08-30       Impact factor: 0.840

Review 7.  Intra-aortic balloon pump counterpulsation in the setting of subarachnoid hemorrhage, cerebral vasospasm, and neurogenic stress cardiomyopathy. Case report and review of the literature.

Authors:  Christos Lazaridis; Gustavo Pradilla; Paul A Nyquist; Rafael J Tamargo
Journal:  Neurocrit Care       Date:  2010-08       Impact factor: 3.210

Review 8.  An insight into short- and long-term mechanical circulatory support systems.

Authors:  Markus Ferrari; Peter Kruzliak; Kyriakos Spiliopoulos
Journal:  Clin Res Cardiol       Date:  2014-10-28       Impact factor: 5.460

9.  Intra-aortic balloon pumping and thrombocytopenia in patients with acute coronary syndrome : Incidence, risk factors, and prognosis.

Authors:  Z Sheng; H Zhao; H Yan; S Jiang; Y Guan; Y Zhang; L Song; C Liu; P Zhou; K Liu; J Liu; Y Tan
Journal:  Herz       Date:  2017-07-19       Impact factor: 1.443

10.  Safety of intra-aortic balloon pump using glycoprotein IIb/IIIa antagonists.

Authors:  Avishag Laish-Farkash; Hanoch Hod; Shlomo Matetzky; Victor Guetta
Journal:  Clin Cardiol       Date:  2009-02       Impact factor: 2.882

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.